Nivolumab with or Without Ipilimumab in Patients with Recurrent or Metastatic Cervical Cancer (checkmate 358): a Phase 1–2, Open-Label, Multicohort Trial
LANCET ONCOLOGY(2024)
Key words
Tumor Microenvironment
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined